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Abstract 
Background:  Severity of cerebral venous thrombosis (CVT) may require the transfer to intensive care unit (ICU). This 
report described the context for CVT transfer to ICU, the strategy of care and the outcome after 1 year.
Methods: Monocentric cohort of 41 consecutive CVT admitted in a French ICU tertiary hospital (National Referent 
Center for CVT). Data collected are as follows: demographic data, clinical course, incidence of craniectomy and/or 
endovascular procedures and outcome in ICU, after 3 and 12 months.
Results:  47 years old (IQ 26–53), with 73.2 % were female, having a SAPS II 41 (32–45), GCS 7 (5–8), and at least 
one episode of mydriasis in 48.8 %. Thrombosis location was 80.5 % in lateral sinus and 53.7 % in superior sagittal 
sinus; intracranial hematoma was present in 78.0 %, signs of intracranial hypertension in 60.9 %, cerebral edema in 
58.5 % and venous ischemia in 43.9 %. All patients received heparin therapy, and 9 cases had endovascular treatment 
(21.9 %); osmotherapy (53.7 %) and decompressive craniectomy (16 cases, 39 %) necessary to control intracranial 
hypertension. Ten patients/41 (24.4 %) died in ICU and 18/31 (58.1 %) were discharged from ICU with outcome 0–3 of 
mRS. After 12 months, 92 % of survivors (23/25) had a mRS between 0 and 3. The proportion of death was 31.7 % at 
1 year.
Conclusions:  The large proportion of acceptable outcome in survivors, which continue to functionally improve 
after 1 year, motivates the hospitalization in ICU for severe CVT. For similar CVT severity, craniectomy did not improve 
outcome in comparison with the absence of craniectomy.
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Background
Cerebral venous thrombosis (CVT) is a difficult diagnosis 
of a rare brain vascular disease accounting for 0.5–1 % of 
all strokes [1, 2]. In the largest international multicenter 
cohort of CVT including 624 patients (ISCVT) with large 
spectrum of presentation, Ferro et al. showed a mortality 
rate of 4.3 % at the acute phase and 8.3 % at the last fol-
low-up (16 months) [3]. The authors mentioned 26 cases 
(4.1  %) with severe clinical presentations, but with elu-
sive clinical information and care strategies and intensive 
care unit (ICU) hospitalization or not. Using the same 
database, the authors have reported [4] the main causes 
of death. Transtentorial herniation due to a unilateral 
focal mass effect or to diffuse edema and multiple paren-
chymal lesions were independent predictors of death. 
Coma [5], mental disturbance of deep CVT thrombosis, 
right intracerebral hemorrhage and posterior fossa lesion 
[3] were also associated with poor outcome. Recently, a 
study from multicenter registry had reported the out-
come of 69 patients having decompressive craniectomy 
[6]. If 31 patients came from the previously published 
registry, 34 were new cases or case reports. Although 
no information about incidence of ICU hospitalization, 
neuro-resuscitation and neuro-monitoring was men-
tioned, authors have reported unfavorable outcome (50 % 
of modified Rankin score (mRS) 4 or 5; or 42  % to die) 
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when bilateral lesions were present compared to 11 % in 
unilateral lesions.
In our knowledge, there is no article on strategy of 
care and outcome of CVT patients requiring ICU admis-
sion. This study reports the profile of severe CVT trans-
ferred to ICU, the monitoring used, the strategy of care 
(supportive and instrumental interventions) with the 




Among the patients admitted to the neurological depart-
ment of our institution (National Reference Center for 
CVT), some cases were transferred from 2002 to 2015 
to our ICU for the following indications: severe altera-
tion of consciousness or coma, status epilepticus, intrac-
ranial hypertension and/or requirement of mechanical 
ventilation. The diagnosis of CVT was usually established 
before ICU admission in all cases by CT (computerized 
tomography), venography, MRI (magnetic resonance 
imaging) or MRI combined with MR venography (MRV) 
and/or angiography.
The recorded clinical data were age, sex, medical his-
tory with special focus on malignancy and other known 
risk factors [3, 7, 8]. Clinical severity at ICU admission 
was evaluated by SAPS II, coma was graded with Glas-
gow Coma Scale (GCS), and presence of seizure, mydria-
sis and elevated intracranial pressure (ICP) (CT scan) 
were collected, as well as routine laboratory tests. The 
delay between the onset of neurological symptoms and 
ICU admission or between the diagnosis and ICU admis-
sion was also recorded.
Brain imaging techniques were as follows: CT scan, 
MRI and MRV interpreted by an independent radiologist 
(JPG). This evaluation had to mention the number and 
topography of the venous and sinus thrombosis, presence 
of hematoma, the associated brain damages related to 
venous congestion and presence of hydrocephalus.
The ICU strategy of care aimed to improve cerebral 
perfusion and oxygenation by classic means (central 
temperature <38  °C; arterial partial pressure in CO2 
PaCO2  =  40; cerebral perfusion pressure >65  mmHg; 
and rigorous control of fluid balance). Monitoring con-
sisted in invasive intra-arterial pressure (radial or femoral 
artery), end-tidal CO2 and middle cerebral artery tran-
scranial Doppler velocities (Waki, Atys Medical, France; 
Ultrasound Echo-Doppler Vivid, General Electrics, USA). 
Treatment of CVT was based on heparin anticoagula-
tion at therapeutic dose for all patients. The resistance 
to heparin was carefully checked by the delay to reach 
an adequate aPTT (activated partial thrombin time) 
(between two to three times of control). Interventional 
therapy such as invasive endovascular and neurosurgi-
cal lifesaving techniques was discussed collegially. Since 
venous circulation has a low intravascular pressure, 
moderate intracranial hypertension may impair venous 
flow, justifying the craniectomy. Endovascular treatment 
was decided when anticoagulation and control of cer-
ebral perfusion and oxygenation were adequate but with 
occurrence of signs of uncontrolled intracranial hyper-
tension. A CT scan was always performed before inter-
vention to analyze the mass effect or the disappearance of 
cortical sulci and herniation.
Neurological complications were quoted and corre-
sponded to a new episode of seizure, a new focal sign, 
new episode of hemorrhage or worsening of hematoma 
and post-interventional intracranial infection. The fol-
lowing extra-neurological complications were collected: 
remote thromboembolic episode, anticoagulation com-
plications (extracranial bleeding and heparin-induced 
thrombocytopenia) and nosocomial infections.
The outcome study had consisted in evaluation of 
ICU death, a mRS at ICU discharge, repeated at 3 and 
12  months and more when possible. Post-ICU outcome 
data were obtained from external consults made by a 
neurologist. As previously reported [6], the functional 
outcome was classified as follows: good recovery: mRS 
from 0 to 3; poor recovery: mRS 4 or 5; and death (mRS 
6). The impact of craniectomy and/or endovascular treat-
ment on death rate and functional outcome was also 
evaluated.
Statistical analysis
Clinical and biological quantitative variables were 
expressed as median and 25th–75th interquartiles. Inter-
group comparisons were made by a Mann–Whitney test 
for quantitative variables and Chi-square test with Fis-
cher correction for qualitative variables. A p < 0.05 was 
considered as statistically significant.
Results
Admission in ICU
Forty-seven patients with severe CVT were admitted 
in the ICU from 2002 to 2015 (Fig. 1). Six patients were 
excluded from the analysis because CVT occurred in a 
surgical context of ear–nose–throat infection or facial 
cellulitis (n  =  5) or complicating intracranial surgery 
(meningioma, n =  1). Characteristics of the 41 remain-
ing patients are summarized in Table  1, with a mean 
age 47  years (26–53), 73.2  % female, a SAPS II 41 (32–
45). The main risk factors for CVT were summarized 
in Additional file  1. Reasons for ICU admission were a 
rapid alteration in consciousness [GCS 7 (5–8)], associ-
ated with seizure for 20 patients (48.8 %) and mydriasis 
for 20 patients (48.8 %). Twenty-five patients (60.9 %) had 
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marked CT scan symptoms of elevated ICP. Before ICU 
admission, around two-thirds of patients received hepa-
rin treatment. Early intubation (within 48 h) was neces-
sary in 37 patients (90.2 %).
Topography of brain lesions
The diagnosis of CVT was made before ICU admission 
by imaging techniques (CT scan and angio-CT scan, 
MRI and MRV) in 100  %. A combination of imaging 
techniques to diagnose CVT was necessary in 73.2 % of 
patients. Topography for thrombosis was listed in Addi-
tional file 2: 80.5 % being in lateral sinuses, 53.7 % in the 
superior sagittal sinus and 26.8 % in a deep cerebral vein, 
a recognized risk factor for death. Thrombosis in 3 or 
more venous axes was observed in 51.2 %. The associated 
lesions are listed in Table  2, with hematoma in 78.0  %, 
cerebral edema in 58.5 % and venous ischemia in 43.9 %. 
Unilateral lesions (hematoma and parenchymal ischemia) 
were present in 43.4 %, and bilateral lesions were present 
in 36.6 %.
ICU treatment
All patients were treated in ICU with unfractioned hep-
arin targeting an aPTT ratio >2. This goal was obtained 
within the first 48  h in 30 patients (80.5  %). Cerebral 
perfusion was evaluated by transcranial Doppler in 32 
patients (78.0 %) helping to optimize the strategy of care. 
In few cases (n = 8), intracranial pressure was monitored 
despite the risk of bleeding. When decided, the improve-
ment in cerebral perfusion pressure required norepi-
nephrine infusion in 26 patients (63.4 %), and 22 patients 
(53.7 %) had an osmotherapy to reduce cerebral edema.
Interventional treatment for thrombosis
Sixteen patients (39 %) had an early (48 h) craniectomy 
that was associated with evacuation of hematoma (n = 5) 
and cerebral spinal fluid (CSF) drainage (n  =  4). Two 
patients had the 3 interventions. Nine patients under-
went in  situ endovascular treatment because of neu-
rological deterioration or lack of improvement: 3 had a 
thrombectomy alone; 1 had a thrombolysis only; and 5 
had a combination of the 2 treatments. In 6 patients, the 
venous circulation was restored with only 1 major paren-
chymal bleeding. The presence of severe intracranial 
hypertension is required to evacuate hematoma (n = 2), 
to perform a CSF drainage (n = 7) and/or to perform a 
craniectomy [uncontrolled pressure (n = 4)].
Outcome
The total of dead patients after 1 year was 13/41 (31.7 %). 
Ten patients died in ICU (24.4  %) having similar delay 
between initial symptoms and diagnosis compared to 
survivors, with a more rapid deterioration to be trans-
ferred to ICU (p =  0.029) (Table  1). The clinical profile 
of dead patients compared to survivors was: predomi-
nance of female (p = 0.039), a worse initial GCS [4 (3–6); 
p = 0.0004], a more frequent mydriasis (100 vs. 32.3 %, 
p  =  0.0001) with more frequent signs of intracranial 
hypertension on imaging techniques (p  =  0.003), with 
a trend for more frequent use of norepinephrine (90 
and 54.8  %, respectively) and more difficulty achieving 
therapeutic anticoagulation (50 vs. 80.6 %, respectively). 
Location of thrombosis, topography of parenchymal 
lesions or therapeutic strategy did not differ between 
the two groups (Tables 1, 2, and Additional file 2), with 
a trend for more frequent intracranial hematomas (100 
and 70.9  %, respectively). Death rate was surprisingly 
the same when lesions were unilateral or bilateral (12.2 
vs. 12.  %). The 16 patients who underwent decompres-
sive craniectomy did not differ from others CVT at ICU 
admission, but received norepinephrine more frequently 
(p  =  0.018). They had frequent hematomas (93.8 and 
68 %, respectively) and an anticoagulation more difficult 
to be adequate within 2 days (56.3 and 84 %, respectively). 
These patients had a similar 1-year outcome compared to 
patients who were not treated by craniectomy, although 
the mRS at ICU discharge and after 3 months tended to 
be worse (Additional file  3). The 9 patients who under-
went an endovascular treatment were similar to the oth-
ers, but tended to have more mydriasis (77.8 vs. 40.6 %, 
p = 0.067) and received more frequently norepinephrine 
infusion (p = 0.015). Their mortality rate in ICU and the 
mRS at discharge did not differ from the other patients 
(Additional file 3).
Despite maximal treatment, among the 10 patients who 




Alive at ICU 
discharge  n = 31
Alive at 3 months
n = 26
Death after 3 
months  n = 1
Post-operative
n = 6
Death before 3 
months  n = 2
ICU deaths
n = 10
Lost at 3 months
n = 3
Alive at one year
n = 25
Fig. 1 Flowchart of the CVT cohort along the survey period. Along 
the 13‑year survey period, 47 patients were recruited. Six were 
excluded because a postoperative context (ENT surgery and one 
meningioma surgery). “Spontaneous medical” CVT were finally col‑
lected: 10 died in ICU, 3 died after ICU discharge and 3 were lost; 25 
are currently alive and were studied for functional outcome after at 
least 1 year evolution
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Table 1 ICU admission main characteristics, supportive therapies, outcome for all patients and ICU survivors or dead
Median and interquartile or proportion p < 0.05 were considered as statistically significant. CVT cerebral vein thrombosis, ICU intensive care unit, SAPS II: Simplified 
Acute Physiology Score II, GCS Glasgow Coma Scale, aPPT activated partial thromboplastin time, CSF cerebral spinal fluid. IV intravenous, MAP mean arterial pressure, 








Age (years) 47 (26–53) 44.5 (30.8–52) 47 (24–51.5) 0.82
Sex female (%) 30 (73.2) 10 (100) 20 (75.6) 0.039
SAPS II 41 (32–45) 42.5 (41–52.5) 35 (31.5–44.5) 0.072
Delay for diagnosis (days) 3 (1–7) 3 (1–5.5) 3 (1–7) 0.73
Delay diagnosis–ICU admission (days) 1 (0–3) 0 (0–1) 1 (1–4.5) 0.029
GCS (lowest) 7 (5–8) 4 (3–6) 8 (6–9) 0.0004
Seizure in ICU [n (%)] 18 (43.9) 4 (40) 14 (45.2) 1.00
Mydriasis [n (%)] 20 (48.8) 10 (100) 10 (32.3) 0.0001
Hematoma [n (%)] 32 (78.0) 10 (100) 22 (70.9) 0.083
Heparin before admission [n (%)] 25 (60.9) 5 (50) 20 (75.6) 0.47
aPTT ratio > 2 within 48 h [n (%)] 30 (80.5) 5 (50) 25 (80.6) 0.098
Craniectomy (n (%)) 16 (39.0) 5 (50) 11 (35.5) 0.47
Endovascular treatment [n (%)] 9 (21.9) 3 (30) 6 (19.4) 0.66
CSF shunt [n (%)] 7 (17.7) 2 (20) 5 (16.1) 1.00
IV norepinephrine [n (%)] 26 (63.4) 9 (90) 17 (54.8) 0.063
MAP min day 1 (mmHg) 76 (66–86) 83 (70–98) 76 (65–83) 0.23
MAP min day 2 (mmHg) 75 (71–84) 73 (59–91) 76 (72–83) 0.56
Mechanical ventilation [n (%)] 37 (90.2) 10 (100) 27 (87.1) 0.55
Fluid balance day 1 (mL) −188 (−482 to +393) −350 (−1224 to −145) −188 (−440 to +429) 0.45
Fluid balance day 2 (mL) 247 (−756 to +809) −50 (−679 to +878) 344 (−782 to +797) 0.59
Natremia day 1 (mM) 138 (135–142) 139 (137–141) 137 (135–142) 0.64
Platelet count day 1 (109/L) 231 (181–305) 210 (162–239) 240 (205–309) 0.23
Glycemia day 1 (mM) 7.1 (6.1–8.3) 7.5 (6.2–10.8) 7.1 (5.9–7.8) 0.19
mRS at discharge 4 (3–5) 6 3 (2.5–4) –
mRS at 3 months (n = 23) 3 (2–4) – 3 (2–4) –
mRS at 12 months (n = 18) 2 (1–3) – 2 (1–3) –
mRS at last follow‑up 2 (1–6) 6 2 (0.5–3) –
Table 2 Types of brain damage related to CVT in whole cohort, and ICU survivors or death
p < 0.05 was considered as statistically significant







Hematomas and hemorrhagic transformations 32 (78.0) 10 (100) 22 (70.9) 0.083
 Left hemisphere 10 (24.4) 3 (30) 7 (22.6) 0.68
 Right hemisphere 6 (14.6) 1 (10) 5 (16.1) 1.00
 Both hemispheres 14 (34.1) 5 (50) 9 (29.0) 0.26
 Median structures 9 (21.9) 3 (30) 6 (19.4) 0.66
 Posterior fossa 3 (7.3) 1 (10) 2 (6.5) 1.00
 ≥2 hematomas 16 (39.0) 6 (60) 10 (32.3) 0.15
Intracranial hypertension 25 (60.9) 10 (100) 15 (48.4) 0.003
Cerebral edema 24 (58.5) 7 (70) 17 (54.8) 0.48
Venous ischemia 18 (43.9) 6 (60) 12 (38.7) 0.29
Subarachnoid hemorrhage 8 (19.5) 3 (30) 5 (16.1) 0.38
Hydrocephaly 5 (12.2) 1 (10) 4 (12.9) 1.00
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uncontrolled ICHT or brain herniation and 1 patient died 
from massive pulmonary embolism. Observed ICU com-
plications were as follows: seizures (n = 18); deterioration 
of hemorrhagic lesions under heparin treatment (n  =  8, 
19.5 %); nosocomial infections (craniectomy wound infec-
tion or ventriculitis, n = 4); pneumonia (n = 18, 43.9 %); 
urinary tract infections (n = 5, 12.2 %); and complications 
related to heparin treatment (n  =  5): heparin-induced 
thrombocytopenia (n  =  1), gastric hemorrhage (n  =  1), 
gynecologic bleeding (n =  1), mesenteric hematoma with 
hemorrhagic shock (n = 1) and inguinal hematoma (n = 1).
After ICU discharge (3, 12  months, or later), 3 addi-
tional deaths occurred for different reasons such as brain 
tumor, limitation of treatment or unknown context. 
Among the 31 patients discharged from ICU, 18 patients 
(58.2  %) were classified as “good outcome” (mRS 0–3). 
Since 3 patients were lost for the follow-up at 3 months, 
the proportions were adjusted accordingly. mRS further 
improved along the survey period to 74.1 % (n = 20/23) 
at 3  months and 88.5  % (n  =  23/26) at 1  year. Only 2 
patients only had a mRS at 4–5 after 1 year (Fig. 2). For 
the patients who could be followed over 1 year (n = 19), 
57.9  % (11/19) continued to improve the median mRS 
from 2 to 1 (median survey: 28 months).
Discussion
The study first reports a cohort of patients with severe 
CVT admitted and treated in ICU, which provides 
information on clinical profile, management and out-
come. The mortality of our cohort is higher than the one 
reported on patients having craniectomy [6], for whom 
little is known on clinical situation. However, the sur-
vivors of our cohort of very severe patients had a func-
tional outcome almost identical to the one published in 
the ISCVT cohort having only 4 % of severe presentation 
[3]. Our patients had a mRS between 0 and 3 in 88.5 %, a 
proportion similar to the 89.5 % in ISCVT cohort, who 
were not all treated in ICU. This suggests an effectiveness 
of both ICU care with tight monitoring associated with 
multi-disciplinary strategy discussion.
Characteristics and outcome
Apart from the severity, our cohort appeared similar for 
clinical characteristics to previous publications group-
ing all types of CVT. The patients were predominantly 
female, young, with multi-site thrombosis (thrombo-
sis of superior sagittal sinus in 53.7 and 80.5 % in lateral 
sinuses) and classic risk factors for CVT, but with dif-
ferent proportions compared to previous reports [3]. 
In the ISCVT cohort, 31  % had a lesion dominated by 
hematoma, which was 78.0 % in our cohort, an incidence 
that may explain the severity justifying ICU hospitaliza-
tion. Few patients in ISCVT study had criteria for ICU 
admission (1.1 % of mechanical ventilation, 1.4 % surgery 
and 1.6 % shunts), proportions that largely differed from 













































Total mRS 0-3 mRS 4-5 mRS 6 
12 monthsa
b
12 months (n=26) 
3 months (n=28) 
Discharge (n=31) 
mRS 0 mRS 1 mRS 2 mRS 3 mRS 4 mRS 5 mRS 6 




6.5% 6.5% 6.5% 
10.7% 7.2% 21.4% 32.1% 10.7% 10.7% 7.2% 
15.4% 19.2% 30.8% 
3.9% 
Fig. 2 Outcome of severe CVT from ICU discharge to the next 12 months. a The evolution of the distribution of patients along the survey period 
with white bars for the number of the patients. At each period of monitoring (in ICU, at ICU discharge, 3 and 12 months), patients are divided into: 
group “good recovery” mRS 0–3 (light gray bars), “poor recovery” mRS 4–5 (dark gray bars) and death mRS 6 (black bars). b The distribution of mRS 
along the survey period at ICU discharge, 3 and 12 months. Proportion for functional ranking was calculated as a ratio between mRS value divided 
by the number of patients at the time of evaluation. Patients lost after discharge were excluded
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our cohort, 10 patients died (31.3  %) during ICU stay. 
All patients deceased in ICU had an intracranial hema-
toma associated with lateral sinus thrombosis, previously 
reported to be a risk of death [4, 9]. Importantly, the uni-
lateral or bilateral lesions had non-difference in mortality 
(12.2 % for both), a very different results when compared 
to the study on multiple registry [6]. Although being 
more severe in our cohort, the survivors had similar rate 
of good outcome around 90 % after at least 1 year of evo-
lution than those reported by others [3, 10–12].
Despite a worse functional outcome at ICU discharge, 
survivors had a positive evolution along the survey 
period: at the 1  year, only two patients over 26 (7.8  %) 
had a mRS at 4–5 and 4/26 (15.4 %) had a mRS 0. From 
3  months till 1  year, functional outcome continued to 
improve as reported previously (Fig. 2) even for patients 
treated with invasive procedures such as craniectomy. 
Recently, the outcome and intracranial lesions of 69 
patients with 45 treated by craniectomy were reported 
by Ferro et  al. [6], with no information on ICU admis-
sion and strategy of care. The authors showed a good 
mRS 0–3 for 79 % with 16 % of them dying. The cohort of 
44 craniectomy reported by Aaron et al. [13] had 59.3 % 
of mRS 0–3 at 3 months, a proportion that increased to 
96.2  % after 1  year. Again, little information was given 
on ICU admission and treatment, which limits the com-
parison. Endovascular treatment was performed on 9 
patients in our study for which 6 cases were considered 
successful. Our mortality rate for such patients was simi-
lar (33.3 %) to the one reported in 2008 using endovascu-
lar technique [14].
Strategy of care
In the absence of published ICU treatment in severe 
CVT, our results are difficult to compare. If the use of 
a multimodal neurological monitoring might logically 
help for therapies, this cannot be demonstrated. We 
believe it may help to reduce the delay for management 
decisions, especially for craniectomy and/or endovas-
cular treatment. Since SvjO2 cannot be recommended 
and intracranial pressure monitoring exposes to intrac-
ranial bleeding, the use of transcranial Doppler veloc-
ity, blood pressure, careful control of arterial PaCO2 and 
neurological examination are key parameters to alarm 
on brain hypoperfusion. As an example, the trend for a 
decrease in mean cerebral artery diastolic velocity moti-
vates to perform brain imaging and to discuss the ben-
efit of invasive treatment, such as craniectomy and/or 
endovascular treatment as illustrated in the case report 
shown in Additional file  4. If anticoagulation by hepa-
rin is the hallmark treatment for CVT [15], even when 
intracranial hematoma is present, it might be difficult to 
manage. First, sometimes efficient anticoagulation can be 
obtained after a long delay (>48 h), during which throm-
bosis may worsen. A shift toward another therapy might 
be necessary, such as low molecular weight heparin and/
or endovascular thrombolysis. A long delay to reach 
therapeutic anticoagulation may precipitate to death or 
might indicate decompressive craniectomy, especially in 
the presence of intracranial hematoma. Second, bleeding 
complications may occur as we observed for 8 patients 
having intracranial bleeding and 5 bleeding at different 
peripheral levels. However, after dose adjustment or shift 
to another anticoagulant, the anticoagulation was never 
stopped. If the use of LMW heparin has been suggested 
[16, 17], standard heparin appears safer for intensivist, 
since it can be neutralized if necessary.
Incidence of seizures was high (43.9  %) during ICU 
stay even when the patients were treated before arrival 
(recurrence 88.9  %, 16/18). This context may facilitate 
aspiration pneumonia or ICP elevation. Control of sei-
zure episodes frequently required drug associations.
Craniectomy became in the last 5  years a credible 
treatment to reduce intracranial pressure and second-
ary ischemic lesions after severe CVT, helping the 
venous blood to circulate. Instead of arterial ischemia, 
the low level of venous pressure may push the decision 
to perform the craniectomy for relatively moderate ICP 
elevation. Cortical veins and collapsed veins may then 
recirculate, reducing venous congestion and improving 
venous blood flow in collaterals. In addition, it favors 
anticoagulant to reach the thrombosed venous side [8, 
18]. The positive outcome of craniectomy in this and 
previous reports [6, 19–21] supports its interest to treat 
severe CVT. Consequently, the positioning of this proce-
dure on the therapeutic decision tree will move from the 
rescue indication to a more regular treatment for deterio-
ration of venous congestion despite anticoagulation [7].
The interest of endovascular therapies to improve sur-
vival rate and functional outcome remains speculative 
[14, 22, 23]. If the recanalization of thrombosed profound 
vessels sounds a reasonable goal to obtain a good out-
come [24–26] as observed in our study, it is not clearly 
demonstrated yet. The ongoing randomized clinical trial 
(TO-ACT) comparing thrombolysis (with or without 
thrombosuction)  +  heparin therapy vs. heparin alone 
will perhaps answer this question [27]. Decompressive 
craniectomy plus thrombolysis could be associated in 
the most severe cases, as we report in the case Additional 
file 4 [28, 29].
Limits of the study
First, our study is a one-center study with limited num-
ber cases, even the largest published in ICU. This disad-
vantage can be balanced by the homogenous strategy of 
care for a Reference Center. The ICU team is then well 
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trained to care severe brain injury patients including 
CVT and to initiate meeting after warning from clinic or 
multimodal monitoring items to discuss potential addi-
tional interventional therapy. Second, it is a retrospective 
analysis, which cannot be easily prospective considering 
the low incidence of this disease. Third, the positioning 
of craniectomy and/or endovascular therapies cannot be 
finalized because of the small numbers of cases.
Conclusions
Severe CVT is rare among intensive care patients and 
differs largely from other severe brain injury admitted in 
ICU. An early and aggressive medical strategy is essential 
to prevent intracranial pressure elevation and improve 
venous drainage, which may require decompressive 
craniectomy or endovascular treatment. Despite a very 
severe initial clinical presentation, it is remarkable to 
observe an acceptable rate of death and frequent accept-
able functional prognosis, which continues to improve 
after 1 year, as opposed to arterial brain ischemia.
Abbreviations
aPTT: activated partial thrombin time; CSF: cerebral spinal fluid; CT: computer‑
ized tomography; CVT: cerebral vein thrombosis; GCS: Glasgow Coma Scale; 
ISCVT: International Study on Cerebral Vein and Sinus Thrombosis [3]; ICU: 
intensive care unit; ICP: intracranial pressure; IQ: interquartile; MRI: magnetic 
resonance imaging; mRS: modified Rankin score; MRV: magnetic resonance 
venography; SAPS II: Simplified Acute Physiology Score II.
Additional files
Additional file 1. Risk factors for CVT in ICU from our cohort. Risk factors 
were classified according to conditions described in the literature. The 
association of tobacco and oral contraception was less frequent than in 
the literature. The 3 cases had solid cancer. Hematologic disorders were as 
follows: sickle‑cell disease, myeloproliferative disorder, chronic lymphoid 
leukemia, thrombocytemia, polycythemia, multiple myeloma and autoim‑
mune thrombotic purpura. Miscellaneous cases included diseases such as 
Behçet disease.
Additional file 2. Localization of venous thrombosis with mention for 
lateral sinus, comparing ICU survivors and deaths. p < 0.05 was considered 
as statistically significant.
Additional file 3. Comparison of admission characteristics and support‑
ive therapies intensity between groups having craniectomy, endovascular 
treatment or not.
Additional file 4. Summary of therapeutic decisions for a severe CVT 
case based on multimodal monitoring and imaging. Figure 2a shows low 
transcranial Doppler diastolic velocities (<10 cm/s) with a low cerebral 
perfusion pressure (almost 40 mmHg; high ICP)), which did not improve 
after decompressive craniectomy. A collegially decided thrombectomy 
improved cerebral hemodynamic at day 3, allowing to stop sedation and 
to evaluate clinical symptoms. Figure 2b shows the initial venous‑induced 
ischemia (hypo density), the subarachnoid hemorrhage with cerebral 
edema with narrowed ventricles (first picture). After decompressive 
craniectomy (second picture), ICP was persistently elevated in relation to 
hemorrhagic transformation and cerebral edema. Cerebral arteriography 
showed a non‑recanalized superior sagittal sinus (SSS) despite adequate 
anticoagulation (third picture). After in situ thrombectomy and continu‑
ous thrombolysis, the flow in the SSS was re‑established with a concomi‑
tant decrease in ICP (fourth picture).
Authors’ contributions
BS, MR, ACL and DP wrote the article. BS, MR, ACL and IC have collected the 
data. IC gave a large input about neurological aspects. BS and DP both final‑
ized the final version of the manuscript. All authors read and approved the 
final manuscript.
Author details
1 Department of Anesthesiology and Critical Care and SMUR, Hôpital Lari‑
boisière, AP‑HP, 2 Rue Ambroise Paré, 75010 Paris, France. 2 Université Diderot 
Sorbonne Paris Cité, Paris, France. 3 Département Hospitalo‑Universitaire 
(DHU) Neuro‑Vasculaire, P R E S Paris Sorbonne Cité, Paris, France. 4 Service 
of Neurology, Hôpital Lariboisière, AP‑HP, Université Paris 7 Denis Diderot, Paris, 
France. 5 Department of Neurovascular Imaging, Hôpital Lariboisière, AP‑HP, 
Université Paris 7 Denis Diderot, Paris, France. 6 Service of Neurosurgery, Hôpi‑
tal Lariboisière, AP‑HP, Université Paris 7 Denis Diderot, Paris, France. 
Acknowledgements
Source of Funding: This work was supported in part by a University Grant from 
Ministry of Research (Plan Quadriennal 2009–2013).
Competing interests
IC has been and is still an investigator or an active member of committees for 
several trials testing CVT treatments such as TO‑ACT trial. Other authors have 
no conflict of interest.
Received: 31 December 2015   Accepted: 28 March 2016
References
 1. Bousser M‑G, Ferro JM. Cerebral venous thrombosis: an update. Lancet 
Neurol. 2007;6:162–70.
 2. Einhäupl K, Stam J, Bousser M‑G, De Bruijn SFTM, Ferro JM, Martinelli 
I, Masuhr F. EFNS guideline on the treatment of cerebral venous and 
sinus thrombosis in adult patients. Eur J Neurol Off J Eur Fed Neurol Soc. 
2010;17:1229–35.
 3. Ferro JM, Canhão P, Stam J, Bousser M‑G, Barinagarrementeria F. Prognosis 
of cerebral vein and dural sinus thrombosis: results of the International 
Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke J 
Cereb Circ. 2004;35:664–70.
 4. Canhão P, Ferro JM, Lindgren AG, Bousser M‑G, Stam J, Barinagarremen‑
teria F. Causes and predictors of death in cerebral venous thrombosis. 
Stroke J Cereb Circ. 2005;36:1720–5.
 5. Ferro JM, Bacelar‑Nicolau H, Rodrigues T, Bacelar‑Nicolau L, Canhão P, 
Crassard I, Bousser M‑G, Dutra AP, Massaro A, Mackowiack‑Cordiolani 
M‑A, Leys D, Fontes J, Stam J, Barinagarrementeria F. Risk score to predict 
the outcome of patients with cerebral vein and dural sinus thrombosis. 
Cerebrovasc Dis Basel Switz. 2009;28:39–44.
 6. Ferro JM, Crassard I, Coutinho JM, Canhão P, Barinagarrementeria F, 
Cucchiara B, Derex L, Lichy C, Masjuan J, Massaro A, Matamala G, Poli 
S, Saadatnia M, Stolz E, Viana‑Baptista M, Stam J, Bousser M‑G. Decom‑
pressive surgery in cerebrovenous thrombosis: a multicenter registry 
and a systematic review of individual patient data. Stroke J Cereb Circ. 
2011;42:2825–31.
 7. Saposnik G, Barinagarrementeria F, Brown RD Jr, Bushnell CD, Cucchiara 
B, Cushman M, deVeber G, Ferro JM, Tsai FY. Diagnosis and management 
of cerebral venous thrombosis: a statement for healthcare profession‑
als from the American Heart Association/American Stroke Association. 
Stroke J Cereb Circ. 2011;42:1158–92.
 8. Stam J. Thrombosis of the cerebral veins and sinuses. N Engl J Med. 
2005;352:1791–8.
 9. Girot M, Ferro JM, Canhão P, Stam J, Bousser M‑G, Barinagarrementeria F, 
Leys D. Predictors of outcome in patients with cerebral venous thrombo‑
sis and intracerebral hemorrhage. Stroke J Cereb Circ. 2007;38:337–42.
 10. Dentali F, Poli D, Scoditti U, Di Minno MND, Stefano VD, Siragusa S, Kostal 
M, Palareti G, Sartori MT, Grandone E, Vedovati MC, Ageno W, Falanga 
A, Lerede T, Bianchi M, Testa S, Witt D, McCool K, Bucherini E, Grifoni E, 
Coalizzo D, Benedetti R, Marietta M, Sessa M, Guaschino C, di Minno 
G, Tufano A, Barbar S, Malato A, Pini M, et al. Long‑term outcomes of 
Page 8 of 8Soyer et al. Ann. Intensive Care  (2016) 6:29 
patients with cerebral vein thrombosis: a multicenter study. J Thromb 
Haemost JTH. 2012;10:1297–302.
 11. Narayan D, Kaul S, Ravishankar K, Suryaprabha T, Bandaru VCSS, Mridula 
KR, Jabeen SA, Alladi S, Meena AK, Borgohain R. Risk factors, clinical 
profile, and long‑term outcome of 428 patients of cerebral sinus venous 
thrombosis: insights from Nizam’s Institute Venous Stroke Registry, 
Hyderabad (India). Neurol India. 2012;60:154–9.
 12. Borhani Haghighi A, Edgell RC, Cruz‑Flores S, Feen E, Piriyawat P, Vora N, 
Callison RC, Alshekhlee A. Mortality of cerebral venous‑sinus thrombosis 
in a large national sample. Stroke J Cereb Circ. 2012;43:262–4.
 13. Aaron S, Alexander M, Moorthy RK, Mani S, Mathew V, Patil AKB, Sivadasan 
A, Nair S, Joseph M, Thomas M, Prabhu K, Joseph BV, Rajshekhar V, Chacko 
AG. Decompressive craniectomy in cerebral venous thrombosis: a single 
centre experience. J Neurol Neurosurg Psychiatry. 2013;84:995–1000.
 14. Stam J, Majoie CBLM, van Delden OM, van Lienden KP, Reekers JA. 
Endovascular thrombectomy and thrombolysis for severe cerebral sinus 
thrombosis: a prospective study. Stroke J Cereb Circ. 2008;39:1487–90.
 15. Coutinho J, de Bruijn SF, Deveber G, Stam J. Anticoagulation for 
cerebral venous sinus thrombosis. Cochrane Database Syst Rev Online. 
2011;(8):CD002005. doi:10.1002/14651858.CD002005.
 16. Coutinho JM, Ferro JM, Canhão P, Barinagarrementeria F, Bousser 
M‑G, Stam J. Unfractionated or low‑molecular weight heparin for 
the treatment of cerebral venous thrombosis. Stroke J Cereb Circ. 
2010;41:2575–80.
 17. Misra UK, Kalita J, Chandra S, Kumar B, Bansal V. Low molecular weight 
heparin versus unfractionated heparin in cerebral venous sinus throm‑
bosis: a randomized controlled trial. Eur J Neurol Off J Eur Fed Neurol Soc. 
2012;19:1030–6.
 18. Weber J, Vida M, Greiner K. Sagittal sinus thrombosis with malignant brain 
oedema: pathophysiology of cortical veins after decompressive craniec‑
tomy. Acta Neurochir (Wien). 2013;155:651–3.
 19. Théaudin M, Crassard I, Bresson D, Saliou G, Favrole P, Vahedi K, Denier C, 
Bousser M‑G. Should decompressive surgery be performed in malignant 
cerebral venous thrombosis?: a series of 12 patients. Stroke J Cereb Circ. 
2010;41:727–31.
 20. Lath R, Kumar S, Reddy R, Boola GR, Ray A, Prabhakar S, Ranjan A. Decom‑
pressive surgery for severe cerebral venous sinus thrombosis. Neurol 
India. 2010;58:392–7.
 21. Zuurbier SM, Coutinho JM, Majoie CBLM, Coert BA, van den Munckhof 
P, Stam J. Decompressive hemicraniectomy in severe cerebral venous 
thrombosis: a prospective case series. J Neurol. 2012;259:1099–105.
 22. Ciccone A, Canhão P, Falcão F, Ferro JM, Sterzi R. Thrombolysis for cerebral 
vein and dural sinus thrombosis. Cochrane Database Syst Rev Online. 
2004;(1):CD003693.
 23. Canhão P, Falcão F, Ferro JM. Thrombolytics for cerebral sinus thrombosis: 
a systematic review. Cerebrovasc Dis Basel Switz. 2003;15:159–66.
 24. Dashti SR, Hu YC, Yao T, Fiorella D, Mitha AP, Albuquerque FC, McDougall 
CG. Mechanical thrombectomy as first‑line treatment for venous sinus 
thrombosis: technical considerations and preliminary results using the 
AngioJet device. J Neurointerventional Surg. 2013;5:49–53.
 25. Kumar S, Rajshekher G, Reddy CR, Venkateswarlu J, Prabhakar S. Intrasinus 
thrombolysis in cerebral venous sinus thrombosis: single‑center experi‑
ence in 19 patients. Neurol India. 2010;58:225–9.
 26. Guo X, Guan S, Fan Y, Song L. Local thrombolysis for severe cerebral 
venous sinus thrombosis. AJNR Am J Neuroradiol. 2012;33:1187–90.
 27. Coutinho JM, Ferro JM, Zuurbier SM, Mink MS, Canhão P, Crassard I, 
Majoie CB, Reekers JA, Houdart E, de Haan RJ, Bousser M‑G, Stam J. 
Thrombolysis or anticoagulation for cerebral venous thrombosis: 
rationale and design of the TO‑ACT trial. Int J Stroke Off J Int Stroke Soc. 
2013;8:135–40.
 28. Coutinho JM, Hama‑Amin AD, Vleggeert‑Lankamp C, Reekers JA, Stam J, 
Wermer MJH. Decompressive hemicraniectomy followed by endovas‑
cular thrombosuction in a patient with cerebral venous thrombosis. J 
Neurol. 2012;259:562–4.
 29. Dohmen C, Galldiks N, Moeller‑Hartmann W, Fink GR, Timmermann L. 
Sequential escalation of therapy in “malignant” cerebral venous and sinus 
thrombosis. Neurocrit Care. 2010;12:98–102.
